MDXG- The SG&A is a concern. Those numbers for 2011 are high because they acquired surgical biologies and also were getting there AminoFix and CollaFix to market. If you take a look at the quarterlies those SG&A numbers do come down throughout the year. They still have one more product to get approved, so research and development should come down some. How much is anyones guess.
They are expecting to be free cash flow positive either by quarter 1 or 2. If they exceeded the rev goals, for Q1, they may be there now. It will be an interesting report for sure.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.